Annovis Bio (ANVS) vs Caribou Biosciences (CRBU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annovis Bio (ANVS) has outperformed Caribou Biosciences (CRBU) over the past year, losing 48.5% versus a loss of 82.0%. Over five years, ANVS leads with a -95.8% price change compared with -97.7% for CRBU. Caribou Biosciences is the larger company by market cap ($51.6 million vs $49.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | CRBU |
|---|---|---|
| Share price | $1.17 | $0.4812 |
| Market cap | $49.93M | $51.59M |
| 1-day change | -3.31% | -22.06% |
| YTD return | -66.18% | -69.74% |
| 1-year return | -48.46% | -82.04% |
| 5-year return | -95.82% | -97.69% |
| EPS (TTM) | $-1.75 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $3.54 |
| 52-week low | $1.04 | $0.45 |
| Distance from 52-week high | -78.73% | -86.39% |
| Analyst consensus | none | buy |
| Avg. price target upside | +797.44% | +1094.93% |
| Average volume | 884.63K | 2.14M |
| Shares outstanding | 42.68M | 107.21M |
| Employees | 7 | 97 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANVS has outperformed CRBU by 33.6 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Healthcare · Biotechnology · 7 employees
About Caribou Biosciences
CRBU stock →Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company.
Healthcare · Biotechnology · 97 employees
ANVS vs CRBU FAQ
Which is bigger, Annovis Bio or Caribou Biosciences?
Caribou Biosciences (CRBU) is larger, with a market capitalization of $51.59M compared with $49.93M for Annovis Bio (ANVS).
Which stock has performed better over the past year, ANVS or CRBU?
ANVS returned -48.46% over the past 12 months, compared with -82.04% for CRBU (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and Caribou Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.